D. Crittenden

发表

Favorable skeletal benefit/risk of long-term denosumab therapy: A virtual-twin analysis of fractures prevented relative to skeletal safety events observed.

E. Siris, N. Pannacciulli, N. Binkley, 2020, Bone.

FRAME Study: The Foundation Effect of Building Bone With 1 Year of Romosozumab Leads to Continued Lower Fracture Risk After Transition to Denosumab

A. Grauer, N. Lane, Toshio Matsumoto, 2018, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Colchicine Use and Incident Coronary Artery Disease in Male Patients with Gout.

Binita Shah, M. Pillinger, A. Slobodnick, 2020, The Canadian journal of cardiology.

A Survey of Women's Awareness of and Reasons for Lack of Postfracture Osteoporotic Care

A. Grauer, D. Boudreau, D. Scholes, 2017, Journal of the American Geriatrics Society.

Metrics for evaluating the utility of patient-centered decision tools.

N. Shah, D. Crittenden, 2010, Archives of internal medicine.

Effect of denosumab on fasting glucose in women with diabetes or prediabetes from the FREEDOM trial

E. Vittinghoff, A. Schwartz, N. Pannacciulli, 2018, Diabetes/metabolism research and reviews.

T‐Score as an Indicator of Fracture Risk During Treatment With Romosozumab or Alendronate in the ARCH Trial

P. Ebeling, Toshio Matsumoto, E. Lewiecki, 2020, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Unmasking romosozumab: response to commentsby Uzoigwe et al.

C. Libanati, F. Cosman, D. Crittenden, 2017, Osteoporosis International.

Allopurinol use and type 2 diabetes incidence among patients with gout

M. Pillinger, A. Slobodnick, M. Toprover, 2020, Medicine.

Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trial

Jacques P. Brown, H. Genant, A. Grauer, 2017, The Lancet.

The year in gout - 2010-2011.

M. Pillinger, D. Crittenden, 2011, Bulletin of the NYU hospital for joint diseases.

New therapies for gout.

M. Pillinger, D. Crittenden, 2013, Annual review of medicine.

The year in gout: 2011-2012.

M. Pillinger, D. Crittenden, 2012, Bulletin of the NYU hospital for joint diseases.

Romosozumab for the treatment of postmenopausal osteoporosis

A. Grauer, F. Cosman, D. Crittenden, 2021, Marcus and Feldman's Osteoporosis.

Safety, Pharmacokinetics, Pharmacodynamics, and Formulation of Liver‐Distributed Farnesoid X‐Receptor Agonist TERN‐101 in Healthy Volunteers

Christopher Jones, M. Fenaux, M. Charlton, 2021, Clinical pharmacology in drug development.

Cardiovascular Disease Prevalence in Patients with Osteoarthritis, Gout, or Both.

M. Pillinger, S. Krasnokutsky, C. Tenner, 2016, Bulletin of the Hospital for Joint Disease.

The Crystallization of Monosodium Urate

L. Nazzal, D. Crittenden, Miguel A Martillo, 2014, Current Rheumatology Reports.

Romosozumab Treatment in Postmenopausal Women with Osteoporosis.

A. Grauer, L. Hofbauer, E. Lau, 2016, The New England journal of medicine.

New and emerging therapies for gout

D. Goldfarb, M. Pillinger, Han-Na Kim, 2011 .

Colchicine Use Is Associated with Decreased Prevalence of Myocardial Infarction in Patients with Gout

J. Greenberg, B. Cronstein, M. Pillinger, 2012, The Journal of Rheumatology.

Romosozumab increases bone mineral density in postmenopausal Japanese women with osteoporosis: A phase 2 study.

A. Grauer, C. Libanati, A. Miyauchi, 2017, Bone.

Predictors of imminent risk of fracture in Medicare-enrolled men and women

Yan Hu, R. Barron, D. Chandler, 2020, Archives of Osteoporosis.

Hyperuricemia, Gout, and Related Comorbidities: Cause and Effect on a Two-Way Street

M. Pillinger, D. Crittenden, E. Karis, 2014, Southern medical journal.

Predictors of near-term fracture in osteoporotic women aged ≥65 years, based on data from the study of osteoporotic fractures

G. Oster, A. Grauer, J. Edelsberg, 2017, Osteoporosis International.

Determinants of imminent fracture risk in postmenopausal women with osteoporosis

G. Oster, A. Grauer, D. Weycker, 2020, Osteoporosis International.

Prevalence of contraindications and prescription of pharmacologic therapies for gout.

D. Goldfarb, M. Pillinger, C. Oh, 2011, The American journal of medicine.

Predicting imminent risk for fracture in patients aged 50 or older with osteoporosis using US claims data

M. Bonafede, N. Shi, R. Barron, 2016, Archives of Osteoporosis.

A Model for Assessing the Clinical and Economic Benefits of Bone-forming Agents for Reducing Fractures in Postmenopausal Women at High, Near-term Risk of Osteoporotic Fracture.

Claire E. O’Hanlon, John P. Caloyeras, B. Stollenwerk, 2017, Clinical therapeutics.

Romosozumab FRAME Study: A Post Hoc Analysis of the Role of Regional Background Fracture Risk on Nonvertebral Fracture Outcome

A. Grauer, E. Lewiecki, S. Ferrari, 2018, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Colchicine Use and Major Adverse Cardiovascular Events in Male Patients with Gout and Established Coronary Artery Disease: A Veterans Affairs Nested Retrospective Cohort Study

M. Pillinger, M. Toprover, B. Shah, 2023, Gout, Urate, and Crystal Deposition Disease.

Greater Gains in Spine and Hip Strength for Romosozumab Compared With Teriparatide in Postmenopausal Women With Low Bone Mass

Jacques P. Brown, H. Genant, A. Grauer, 2017, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Increased bone mineral density for 1 year of romosozumab, vs placebo, followed by 2 years of denosumab in the Japanese subgroup of the pivotal FRAME trial and extension

A. Grauer, R. Dinavahi, C. Libanati, 2019, Archives of Osteoporosis.

Gout comorbidities: prevalence and management

M. Pillinger, D. Crittenden, E. Karis, 2013 .

OP0100 Superior Gains in Bone Mineral Density and Estimated Strength at The Hip for Romosozumab Compared with Teriparatide in Women with Postmenopausal Osteoporosis Transitioning from Bisphosphonate Therapy: Results of The Phase 3 Open-Label Structure Study

A. Grauer, T. Keaveny, K. Engelke, 2016 .

Superior Gains in Bone Mineral Density (BMD) and Estimated Strength at the Hip for Romosozumab Compared With Teriparatide (TPTD) in Women With Postmenopausal Osteoporosis Transitioning From Bisphosphonate Therapy: Results of the Phase 3 Open-label STRUCTURE Study

Jacques P. Brown, H. Genant, T. Keaveny, 2016 .

Sweet’s syndrome and systemic lupus erythematosus

M. Bravin, D. Crittenden, N. Gollol-Raju, 2009, Lupus.

Comparison of dual-energy CT, ultrasound and surface measurement for assessing tophus dissolution during rapid urate debulking

M. Pillinger, S. Gyftopoulos, S. Krasnokutsky, 2017, Clinical Rheumatology.

The year in gout: 2012-2013 - a walk through the 2012 ACR Gout Treatment Guidelines.

M. Pillinger, D. Crittenden, 2013, Bulletin of the Hospital for Joint Disease.

FRI0470 EFFECT OF DISCONTINUATION OF DENOSUMAB IN SUBJECTS WITH RHEUMATOID ARTHRITIS TREATED WITH GLUCOCORTICOIDS

P. Geusens, W. Lems, K. Saag, 2019, Osteoporosis.

Greater Gains in Spine and Hip Strength for Romosozumab Compared With Teriparatide in Postmenopausal Women With Low Bone Mass

Jacques P. Brown, H. Genant, A. Grauer, 2017, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.